证券代码：300453 证券简称：三鑫医疗 公告编号：2025-042 江西三鑫医疗科技股份有限公司 关于 2025 年中期利润分配预案的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、江西三鑫医疗科技股份有限公司 2025 年中期利润分配预案为：以 522,237,525 股（已扣除公司回购专用证券账户中的股份 160,000 股）为基数， 向全体股东每 10 股派发现金红利 1 元（含税），不送红股，不进行资本公积金 转增股本，剩余未分配利润结转以后年度。 一、审议程序 江西三鑫医疗科技股份有限公司（以下简称"公司"）于 2025 年 8 月 7 日 召开了第五届董事会第二十一次会议、第五届监事会第十九次会议，审议通过了 《关于 2025 年中期利润分配预案的议案》。现将有关情况公告如下： （一）董事会审议情况 2025 年 8 月 7 日，公司召开的第五届董事会第二十一次会议，审议通过了 《关于 2025 年中期利润分配预案的议案》，董事会认为：此利润分配预案符合 公司实际情况，有利于公司的持续稳定健康发展，有利于保护广大投资者的利益， ...

Core Viewpoint - Sanxin Medical's stock price showed a fluctuating upward trend on August 4, closing at 9.03 yuan, an increase of 0.56% from the previous trading day [1] Company Overview - The company specializes in the research, production, and sales of medical devices, covering various fields such as blood purification, injection, and indwelling catheters [1] - As a significant player in the medical device industry in Jiangxi province, Sanxin Medical holds a certain influence in its niche market [1] Market Activity - On the trading day, the stock experienced a rapid rebound, with a rise of over 2% within five minutes at 9:40 AM, and a transaction amount of 26.77 million yuan [1] - Despite a net outflow of 4.64 million yuan from main funds on that day, the overall trend over the past five trading days showed a net inflow of 7.51 million yuan [1] - The stock recorded a trading amplitude of 3.23%, with a total trading volume of 136,600 hands and a total transaction amount of 122 million yuan [1]

Company Overview - Sanxin Medical focuses on the research, manufacturing, sales, and service of medical devices, with key products including blood purification devices, drug delivery devices, and cardiothoracic surgical products [2] - As of the end of 2024, the company holds 203 authorized patents, 121 pending patents, and has published 26 papers, demonstrating a strong commitment to technological innovation and R&D [2] Financial Performance - In Q1 2025, Sanxin Medical reported revenue of 361 million yuan, an increase of 8.88% year-on-year, and a net profit of 53.73 million yuan, reflecting a slight increase of 0.20% year-on-year [2] - The company's gross profit margin stands at 34.62% [2] Market Position - As of August 1, Sanxin Medical's stock closed at 8.98 yuan, with a rolling PE ratio of 20.62, marking a 553-day low, and a total market capitalization of 4.691 billion yuan [1] - The average PE ratio for the medical device industry is 53.65, with a median of 37.22, placing Sanxin Medical at the 45th position within the industry [1][3] Shareholder Information - As of March 31, 2025, Sanxin Medical has 18,367 shareholders, an increase of 1,327 from the previous count, with an average holding value of 352,800 yuan and an average shareholding of 27,600 shares per shareholder [1]

Group 1 - The core viewpoint of the news is that Sanxin Medical (300453) has shown a positive performance in its stock price and financial results as of July 30, 2025, with a closing price of 8.85 yuan, up 1.49% [1] - The company reported a total operating revenue of 361 million yuan for Q1 2025, representing a year-on-year growth of 8.88%, and a net profit attributable to shareholders of 53.73 million yuan, which is a slight increase of 0.20% year-on-year [1] - The company has a current ratio of 1.619, a quick ratio of 1.229, and a debt-to-asset ratio of 33.83%, indicating a stable financial position [1] Group 2 - Sanxin Medical has made investments in 14 companies and participated in 776 bidding projects, showcasing its active engagement in the market [2] - The company holds 46 trademark registrations and 209 patents, reflecting its commitment to innovation and intellectual property [2] - Additionally, Sanxin Medical possesses 175 administrative licenses, indicating compliance with regulatory requirements [2]

Core Viewpoint - Company emphasizes its commitment to innovation-driven development and ongoing projects in blood purification and related medical fields [2] Group 1: R&D Progress - Company is focusing on enhancing its product range in blood dialysis and expanding into diabetes, early-stage kidney disease, and vascular intervention [2] - Currently, there are over 30 projects under research, including key materials for dialysis membranes [2] - The company is collaborating with industry partners to develop domestic production technology for medical-grade polyethersulfone [2] - Ongoing projects include artificial blood vessels, anticoagulant-coated catheters, plasma separators, and blood loss monitors, which have received various provincial and national support [2] Group 2: Market Value Management - Company is actively implementing market value management strategies in accordance with regulatory guidelines [2] - A market value management system has been established, focusing on core business and improving operational efficiency [2] - The company has initiated stock incentive plans in 2018, 2021, and 2024, and is committed to enhancing shareholder returns [2] - Future plans for share buybacks or cancellations will be disclosed in compliance with legal requirements [2]

本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 证券代码：300453 证券简称：三鑫医疗 公告编号：2025-037 江西三鑫医疗科技股份有限公司 关于对外投资暨香港全资子公司完成注册登记的公告 一、对外投资概述 商业登记证号码：78496932-000-07-25-8 江西三鑫医疗科技股份有限公司（以下简称"公司"）于2025年7月1日召开了 第五届董事会第二十次会议，审议通过了《关于对外投资在香港设立全资子公司的 议 案 》 ， 具 体 内 容 详 见 公 司 于 2025 年 7 月 2 日 在 巨 潮 资 讯 网 （http://www.cninfo.com.cn）披露的《关于对外投资在香港设立全资子公司的公 告》（2025-034）。 二、香港全资子公司注册登记情况 近日，公司完成了香港全资子公司的注册登记手续，并取得香港特别行政区公 司注册处签发的《公司注册证明书》和《商业登记证》，具体信息如下： 公司中文名称：三鑫医疗科技（香港）有限公司 公司英文名称：Sanxin Medtec (Hong Kong)Co.,Limited 注册资本：10 万美元 ...

Group 1 - The core business of the company is the research, manufacturing, sales, and service of medical devices, with main products including blood purification, drug delivery devices, and thoracic surgery products [2] - As of the end of 2024, the company has obtained 203 authorized patents, 121 accepted patents, and holds 102 medical device product registration certificates, demonstrating a strong focus on technological innovation and R&D [2] - The company has received various governmental support for its projects, including recognition as a "National Intellectual Property Advantage Enterprise" and awards for its key technologies in blood dialysis membrane production [2] Group 2 - The company's latest financial performance for Q1 2025 shows revenue of 361 million yuan, an increase of 8.88% year-on-year, and a net profit of 53.73 million yuan, with a slight increase of 0.20% year-on-year [2] - The company's current rolling P/E ratio is 19.93, which is significantly lower than the industry average of 55.41 and the industry median of 37.94 [1][3] - The total market capitalization of the company is 4.534 billion yuan, ranking it 41st in the medical device industry [1][3]

证券代码：300453 证券简称：三鑫医疗 公告编号：2025-036 制品销售，专业保洁、清洗、消毒服务，化 妆品批发，化妆品零售，生物基材料技术研 发，医学研究和试验发展，技术服务、技术 开发、技术咨询、技术交流、技术转让、技 术推广，信息咨询服务（不含许可类信息咨 询服务）（除依法须经批准的项目外，凭营 业执照依法自主开展经营活动） 项目外，凭营业执照依法自主开展经营活 动） 二、营业执照基本登记信息 名称：江西圣丹康医学科技有限公司 江西三鑫医疗科技股份有限公司 关于全资子公司完成工商变更登记的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 江西三鑫医疗科技股份有限公司全资子公司江西圣丹康医学科技有限公司因经 营发展需要，对经营范围进行了变更，并于近日取得了由赣江新区行政审批局换发 的《营业执照》。工商变更情况如下： 一、工商信息变更情况 | 变更 | 变更前内容 | 变更后内容 | | --- | --- | --- | | 事项 | | | | | 许可项目：药品生产，药品批发，药品零售， | 许可项目：药品生产，药品批发，药品零售， | | | ...

证券代码：300453 证券简称：三鑫医疗 公告编号：2025-035 江西三鑫医疗科技股份有限公司 关于变更医疗器械生产许可证的公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 江西三鑫医疗科技股份有限公司（以下简称"公司"）因生产经营需要，对《医 疗器械生产许可证》的生产范围进行变更并完成了变更登记手续，于近日取得了江 西省药品监督管理局换发的《医疗器械生产许可证》，现将具体内容公告如下： | 变更 事项 | 变更前内容 | 变更后内容 | | --- | --- | --- | | | Ⅱ类：08-05 呼吸、麻醉、急救设备辅助装 | Ⅱ类：08-05 呼吸、麻醉、急救设备辅助装 | | | 置；08-06 呼吸、麻醉用管路、面罩；14-02 | 置；08-06 呼吸、麻醉用管路、面罩；14-02 | | | 血管内输液器械；14-05 非血管内导（插） | 血管内输液器械；14-05 非血管内导（插） | | | 管；14-06与非血管内导管配套用体外器械； | 管；14-06 与非血管内导管配套用体外器械； | | | 14-09 不可吸收外科敷料；1 ...

Core Viewpoint - Jiangxi Sanxin Medical Technology Co., Ltd. is expanding its international presence by establishing a wholly-owned subsidiary in Hong Kong to enhance cooperation and business development in overseas markets [2][7]. Company Overview - Jiangxi Sanxin Medical Technology Co., Ltd. (stock code: 300453) is a national high-tech enterprise focused on the research, manufacturing, sales, and service of medical devices, established in 1997 and is the first A-share listed company in Jiangxi Province's medical device industry [3]. - The company's core business includes blood purification products such as hemodialysis machines and related consumables, making it one of the first companies in the industry to develop a complete product chain independently [3][9]. - The company also produces drug delivery devices, including injection and infusion products, continuously upgrading its offerings to meet market demands [6]. Financial Data - In 2024, the company achieved a revenue of 1.5 billion yuan, representing a year-on-year growth of 15.41%. The net profit attributable to shareholders was 227 million yuan, reflecting a growth of 10.05% compared to the previous year [10]. Product and Market Expansion - The company has a strong market presence, with products sold in over 30 provinces and regions in China and exported to more than 60 countries worldwide. The global competitiveness of its blood purification equipment is expected to strengthen, with a rapid increase in export orders [9]. - Sanxin Medical has obtained 43 patents and established long-term partnerships with several universities and top-tier hospitals, achieving various quality certifications including CE, CMD, and FDA510(k) [9]. - The company is accelerating the development of other blood purification treatment models, further solidifying its industry position [9].